论文部分内容阅读
目的评估呋喃妥因在治疗产超广谱β-内酰胺酶(ESBL)大肠杆菌相关性下尿路感染中的疗效。方法筛选经泌尿科门诊和病房确诊的下尿路感染患者173例,收集所有患者清洁中段尿进行尿培养及药敏试验。所有患者口服呋喃妥因胶囊50mg,6h/次,疗程为14d,治疗后7～9d进行尿培养。主要观察治疗后临床和微生物学治愈率、再感染率和复发率以及药物不良反应。结果所有患者中122例(70.5%)患者临床治愈,其中复杂性和非复杂性下尿路感染患者的临床治愈率无明显差异(P>0.05);119例(68.8%)患者微生物学治愈,其中复杂性下尿路感染患者的微生物学治愈率低于非复杂性患者(P<0.05)。再感染率6.8%,复发率2.7%,2例患者出现恶心。结论呋喃妥因可用于治疗产ESBL大肠杆菌相关性下尿路感染,尤其是非复杂性下尿路感染。
Objective To evaluate the efficacy of nitrofurantoin in the treatment of ESBL-associated E. coli-associated urinary tract infections. Methods Seventy-three patients with lower urinary tract infection diagnosed by urology clinics and wards were screened. Urine culture and drug susceptibility tests were performed on all patients with clean middle urine. All patients oral nitrofurantoin capsules 50mg, 6h / time, treatment for 14d, 7 ~ 9d after treatment for urinary culture. The main observation after treatment of clinical and microbiological cure rate, re-infection rate and recurrence rate and adverse drug reactions. Results 122 patients (70.5%) were cured clinically in all patients, and there was no significant difference in the clinical cure rate between complicated and non-complicated lower urinary tract infection patients (P> 0.05); 119 patients (68.8% The complexity of lower urinary tract infection in patients with lower cure rate of microbiology than non-complex patients (P <0.05). Re-infection rate was 6.8%, the recurrence rate was 2.7%, nausea in 2 patients. Conclusions Nitrofurantoin can be used in the treatment of ESBL-associated Escherichia coli-associated lower urinary tract infections, especially noncomplex lower urinary tract infections.